Bonk (SHOT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
16 Oct, 2026Executive summary
Virtual annual meeting scheduled for December 11, 2026; record date October 14, 2026. Stockholders are asked to elect six directors, ratify M & K CPAS, PLLC for FY2026, and approve an equity-plan share reserve of 1,800,000, up from 1,057,143.
The Board recommends FOR all six nominees and both proposals; signed proxies without voting directions will be voted in accordance with those recommendations.
Voting matters and shareholder proposals
Six director nominees will serve until successors are elected at the 2027 annual meeting or earlier resignation or removal; election requires a plurality of votes cast.
Auditor ratification and the equity-plan amendment each require a majority of shares present or represented by proxy and entitled to vote; abstentions count against both proposals.
Director elections and the equity-plan amendment are non-routine; uninstructed brokers cannot vote on them. Auditor ratification is routine, so brokers may vote uninstructed shares.
Stockholder proposals for the 2027 annual meeting must meet Rule 14a-8 requirements and arrive by June 28, 2027; notices for proxy solicitation supporting alternative director nominees are due October 12, 2027.
Board of directors and corporate governance
Six nominees: Jarrett Boon, Christopher Marc Melton, Mitchell Rudy, Connor Klein, James McAvity, and Stacey Duffy; four nominees—Melton, Klein, McAvity, and Duffy—were determined independent under Nasdaq standards.
Board leadership is separated: independent director Melton has chaired the Board since April 2026; Boon serves as CEO. The Board may combine the roles in the future.
Three standing committees have written charters; in FY2025 the Board held five meetings, the Audit Committee four, Compensation Committee two, and Nominating and Corporate Governance Committee one.
During FY2025, directors and officers had late or unfiled Form 3 reports: Rudy, Lucky Dog Holdings, Klein, and Duffy filed late; Russell, McAvity, and former director Richard Pascucci had not yet filed.
Latest events from Bonk
- Revenue surged to $5.5M, but a $7.9M net loss and going concern doubts persist.SHOT
Q2 2026 - Revenue surged in Q1 2026, but liquidity and regulatory risks remain significant.SHOT
Q1 2026 - Shelf registration enables up to $100M in securities sales as company pivots to digital assets.SHOT
Registration filing - 2025 revenue grew to $3.93M, but net loss deepened to $68.2M amid digital asset volatility.SHOT
Q4 2025 - Amended registration for public stock offering, led by CEO Jarrett Boon, with $113K in expenses.SHOT
Registration Filing - Patented dietary supplement business registers shares for resale, funding R&D and growth.SHOT
Registration Filing - Registering 1.9M shares for resale; proceeds from warrants fund R&D and working capital.SHOT
Registration Filing - Patented dietary supplement targets alcohol metabolism, with shares registered for resale on NASDAQ.SHOT
Registration Filing - Registering 1.9M shares for resale, with proceeds from options and warrants funding R&D.SHOT
Registration Filing